[My clinical experience with efalizumab in the Hospital of Conxo].
Psoriasis in plaques is a chronic disease that requires systemic treatment in its moderate and severe forms. Because the need for treatment is generally prolonged, many medications indicated for its treatment cannot be used continuously and have to be replaced by other different drugs, but also with a limited use, both due to their possible side effects, their teratogenicity, the time of use and accumulated dose, among other reasons. The biological drugs have been designed for middle and long term control of the disease. Efalizumab is a drug that has been shown to be effective and safe in patients who have moderate-to-severe psoriasis. We present our results in a group of 50 patients, our special cases, the form in which we have treated the side effects due to Efalizumab and those due to the disease.
Vázquez-Veiga
H A
HA
Servicio de Dermatología, Hospital de Conxo, Complexo Hospitalario Universitario de Santiago de Compostela, A Coruña, España.
Seoane-Pose
M J
MJ
Fernández-Blanco
M T
MT
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005334:Fever / Q000209:etiology; D005500:Follow-Up Studies; D006261:Headache / Q000209:etiology; D006785:Hospitals, University; D006801:Humans; D007964:Leukocytosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy; D011565:Psoriasis / Q000628:therapy*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; C472181:efalizumab